Science Explorer Back to mapMap

Most cited papers from Xilio Therapeutics (United States)

What are the most cited papers from Xilio Therapeutics (United States)?

The most cited paper from Xilio Therapeutics (United States) is "A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants" (Laurie B. Schenkel et al., 2021), with 80 citations. Next come "From Genotype to Phenotype—A Review of Kabuki Syndrome" (69) and "Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models" (32).

Showing 30 of 30 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants Laurie B. Schenkel et al. · Cell chemical biology Open access 11 Mar 2021 80
2 From Genotype to Phenotype—A Review of Kabuki Syndrome Kelly K. Barry, Michaelangelo Tsaparlis, Deborah Hoffman et al. · Genes Open access 29 Sep 2022 69
3 Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models Delphine Valente, Christine Mauriac, Thorsten Schmidt et al. · mAbs Open access 2020 32
4 XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer Kurt A. Jenkins, Miso Park, Magali Pederzoli-Ribeil et al. · Journal for ImmunoTherapy of Cancer Open access Dec 2023 21
5 IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer Timothy Anthony Yap, Alberto Bessudo, Erika Paige Hamilton et al. · Journal for ImmunoTherapy of Cancer Open access Mar 2022 19
6 Hydrophilic Interactions Dominate the Inverse Temperature Dependence of Polypeptide Hydration Free Energies Attributed to Hydrophobicity Dheeraj S. Tomar, Michael E. Paulaitis, Lawrence R. Pratt et al. · The Journal of Physical Chemistry Letters 10 Nov 2020 18
7 XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Ekta P. Patel et al. · Molecular Cancer Therapeutics Open access 29 Nov 2023 14
8 The molecular basis of Human FN3K mediated phosphorylation of glycated substrates Ankur Garg, Kin Fan On, Yang Fan Xiao et al. · Nature Communications Open access 22 Jan 2025 11
9 System Size Dependence of Hydration-Shell Occupancy and Its Implications for Assessing the Hydrophobic and Hydrophilic Contributions to Hydration Dilip N. Asthagiri, Dheeraj S. Tomar · The Journal of Physical Chemistry B 9 Jan 2020 11
10 Terminal alkyne formation by a pyridoxal phosphate-dependent enzyme Jason B. Hedges, Jorge A. Marchand, Carla Calvó‐Tusell et al. · Nature Chemical Biology 25 Jun 2025 7
11 Target binding triggers hierarchical phosphorylation of human Argonaute-2 to promote target release Brianna Bibel, Elad Elkayam, Steve Silletti et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 6 Jan 2022 3
12 Solution structure and dynamics of the mitochondrial‐targeted GTPase ‐activating protein (GAP) VopE by an integrated NMR / SAXS approach Kyle P. Smith, Woonghee Lee, Marco Tonelli et al. · Protein Science Open access 9 Feb 2022 2
13 Analysis of Mutational Signatures Using the mutSignatures R Library Damiano Fantini, Joshua J. Meeks · Methods in molecular biology Book chapter 2023 1
14 El pódcast para democratizar y difundir contenido de calidad en cardiología. El proyecto Mio-Cardio Podcast Aldo L. Schenone · REC CardioClinics 8 Mar 2022 1
15 Dying in the year after surviving: a perspective on elevated all-cause mortality among opioid overdose survivors Robert B. Raffa, Albert Dahan, Joseph V. Pergolizzi et al. · The American Journal of Drug and Alcohol Abuse 18 Sep 2026 0
16 POSTER: MPN-1206: Discovery and Characterization of DMR-001, an Fc-Null, Half-Life–Optimized Monoclonal Antibody Selectively Targeting Mutant Calreticulin Byron Kwan, Shannon Elf, Alexandra Grassian et al. · Clinical Lymphoma Myeloma & Leukemia Aug 2026 0
17 Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly Katherine Kurylo, Page R. Bouchard, Mark Milton et al. · Endocrinology Open access 3 Aug 2026 0
18 Development of an antisense oligonucleotide targeting EFEMP1 in models relevant to macular degeneration William P. Miller et al. · Molecular Therapy — Nucleic Acids Open access 21 Jul 2026 0
19 A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies Anusuya Ramasubramanian et al. · Scientific Reports Open access 3 Jan 2026 0
20 #2438 Discovery and characterization of JADE101, an ultra-high affinity, half-life extended anti-APRIL monoclonal antibody for the treatment of IgAN Erin L. Filbert, Brandon Gufford, Byong Ha Kang et al. · Nephrology Dialysis Transplantation Open access Oct 2025 0
21 1015 ORKA-002, a novel extended half-life monoclonal antibody targeting IL-17A/F for the treatment of psoriatic disease Bethany Matthews Kwan, Joseph Frank Merola, Andrew Blauvelt et al. · Journal of Investigative Dermatology Open access 21 Jul 2025 0
22 ENA-001, an Agnostic Respiratory Stimulant, Reverses Xylazine-Fentanyl Induced Respiratory Depression in Rats Thomas Lloyd Miller, Robert Raffa, George C. Dungan et al. · Drug and Alcohol Dependence Feb 2025 0
23 New Rat Study Suggests a Biologic Basis for Higher Fentanyl Mortality in Men Than Women Robert B. Raffa, Joseph V. Pergolizzi, Jeannette Mathews et al. · Drug and Alcohol Dependence Feb 2025 0
24 A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models Ryan R Kowash, Manoj Kumar Sabnani, Laura T. Gray et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 31 Jul 2024 0
25 758 APG777, a high-affinity humanized IgG1 monoclonal antibody targeting IL-13, demonstrates prolonged half-life and pSTAT6 inhibition in non-human primates E. Zhu, Jae‐Min Oh, Lukas Dillinger et al. · Journal of Investigative Dermatology 19 Jul 2024 0
26 Safety and Tolerability of Ascending Doses of ENA-001: A Novel Respiratory Stimulant, for the Intended Management of Pharmacologically-Induced Respiratory Depression Errol M Gould, Thomas Lloyd Miller, Joseph V. Pergolizzi · Drug and Alcohol Dependence Jul 2024 0
27 Novel ‘Agnostic’ Pharmacologic Approach to Polysubstance Overdose Thomas Lloyd Miller, Amanda M. Bunting, Michael E Schatman et al. · Drug and Alcohol Dependence Jul 2024 0
28 SAXS/MC studies of the mixed-folded protein Cdt1 reveal monomeric, folded over conformations Kyle P. Smith, Srinivas Chakravarthy, Amit Rahi et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 3 Jan 2024 0
29 133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors Diwakar Davar, John George Knecht, Andrae Lavon Vandross et al. · Immuno-Oncology Technology Open access Dec 2023 0
30 Own Your Career: Essential Skills Needed in the Biotech Workforce Tim Hunt, Anjali Angelika Sarkar · GEN Biotechnology Aug 2022 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.